This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?
Prostate Cancer and Prostatic Diseases Open Access 29 November 2022
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Data availability
The data used and/or analyzed are available from the corresponding author on request.
References
Ohlmann CH, Jäschke M, Jaehnig P, Krege S, Gschwend J, Rexer H, et al. LHRH sparing therapy in patients with chemotherapy-naïve, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial. Prostate Cancer Prostatic Dis. 2022. https://doi.org/10.1038/s41391-022-00533-6
Supiot S, Campion L, Pommier P, Dore M, Palpacuer C, Racadot S, et al. Combined abiraterone acetate plus prednisone, salvage prostate bed radiotherapy and LH-RH agonists (CARLHA-GEP12) in biochemically-relapsing prostate cancer patients following prostatectomy: A phase I study of the GETUG/GEP. Oncotarget. 2018;9:22147–22157. https://doi.org/10.18632/oncotarget.25189
Maluf FC, Schutz FA, Cronemberger EH, Luz MA, Martins SPS, Muniz DQB, et al. A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415). Eur J Cancer. 2021;158:63–71. https://doi.org/10.1016/j.ejca.2021.08.032
Mariani S, Salvatori L, Basciani S, Arizzi M, Franco G, Petrangeli E, et al. Expression and cellular localization of follicle-stimulating hormone receptor in normal human prostate, benign prostatic hyperplasia and prostate cancer. J Urol. 2006;175:2072–7. https://doi.org/10.1016/S0022-5347(06)00273-4
Radu A, Pichon C, Camparo P, Antoine M, Allory Y, Couvelard A, et al. Expression of follicle-stimulating hormone receptor in tumor blood vessels. N Engl J Med. 2010;363:1621–30. https://doi.org/10.1056/NEJMoa1001283
Author information
Authors and Affiliations
Contributions
The two authors contributed equally to this paper: LA: Writing—Original Draft, Writing—Review & Editing. SS: Conceptualization, Writing—Review & Editing.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ah-Thiane, L., Supiot, S. Should LHRH therapy be continued in patients receiving abiraterone acetate?. Prostate Cancer Prostatic Dis 25, 798–799 (2022). https://doi.org/10.1038/s41391-022-00584-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-022-00584-9
This article is cited by
-
Reply to RE: Should LHRH therapy be continued in patients receiving Abiraterone Acetate?
Prostate Cancer and Prostatic Diseases (2022)